[Use of immunomodulator derinat in the treatment of patients with surgical sepsis in traumatic shock].
The reparative effects of Derinat were studied in 15 patients with traumatic shock whose state was complicated by the development of sepsis. The immunomodulating effect of the drug lies in increasing the number of lymphocytes, reducing the total number of granulocytes and in elevation of the number of functionally valuable cells in them. Using Derinat was shown to facilitate the restoration of the initially reduced number of blood erythrocytes. The maximum effect of the drug was observed within 3-4 days. Readministrations of Derinat should be made twice a week.
Gromov
M I
MI
Pivovarova
L P
LP
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D004906:Erythrocyte Count; D006098:Granulocytes; D006801:Humans; D007958:Leukocyte Count; D018655:Lymphocyte Count; D018805:Sepsis / Q000097:blood / Q000276:immunology / Q000628:therapy*; D012774:Shock, Traumatic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D013997:Time Factors
D000276:Adjuvants, Immunologic